Molecular red cell genotyping of rare blood donors in South Africa to enhance rare donor-patient blood matching

Introduction

The antigens found on the surface of red blood cells determine the blood type of an individual. Blood grouping is essential for donor-patient blood transfusion match. Red cell antigen mismatch between donor and patient can result in alloimmunisation, which is the formation of red cell antibodies in the patient following transfusion with red cells that the patient lacks. Clinically, alloimmunisation can result in mild to fatal haemolytic transfusion reactions. In neonates, alloimmunisation may cause mild to fatal haemolytic disease of the foetus or newborn.

The current serological phenotyping method of red cell antibody detection used in South Africa is simple and inexpensive. However, inconclusive serology results may result due to the interference from donor red blood cells in chronically transfused patients, a rare blood type causing false-positive results or autoantibodies in patients with autoimmune diseases. Also, sourcing blood for patients with rare blood types is challenging due to the scarcity of commercial rare antisera for serological testing. The term rare blood type describes the absence of an antigen that is found normally in 99% of the country’s population and is described as: ‘negative for high-frequency-antigens (HFA)’ or the presence of antigens found in only 1% of the population termed ‘positive for low-frequency-antigens’ or the presence of an unusual or rare Rh subtype in a very small percentage of the population (1:1000, 1:10 000). Hence, rare commercial antisera are often not readily available and are expensive. Therefore, they are not cost-effective for large-scale blood type screening.

Molecular genotyping overcomes the limitations of serology. The mapping of the human genome provided knowledge on the molecular backgrounds and polymorphisms of the blood
groups that enabled the development of DNA-based assays for red cell genotyping. Genotyping utilises patients’ DNA information to infer the red cell phenotype. Genotyping assays have been widely used in transfusion medicine for over 20 years. This technology only became an affordable service in South Africa in 2015 and has to date not translated into the genetic identification of rare and unique red cell genotypes in South Africa or the wider African context. Smaller studies in some African countries have been completed; however, these were limited to group-specific antigen coverage. Moreover, the sample numbers were too low across the regions to be representative of the African diaspora and its multiple ethnic groups. Therefore, this study aimed to provide the first comprehensive red cell genotyping of rare blood donors referred to the South African National Blood Service, Immunohaematology Reference Laboratory (IRL).

Methods

Ethical considerations

Full approval (ethical clearance number IREC 011/17) was granted by the Durban University of Technology to complete the study as part of a master’s thesis. Ethical approval was also granted by the South African National Blood Service Human Research Ethics Committee (certificate clearance number 2016/06). Initial donor consent was provided by donors when completing the blood donor questionnaire at the time of blood donation. However, there were no human participants in this study as it was a retrospective review of red cell genotyping data only. All genotyping results were anonymised from donor details and blinded using designated study numbers only accessible to the researcher.

Study participants

The South African National Blood Service provides a vein-to-vein blood service in eight of the nine South African provinces and the majority of the blood donations are successfully cross-matched for transfusion to patients. Where routine cross-matching cannot be completed due to inconclusive serology results, the blood donation is referred to the national Immunohaematology Reference Laboratory. This observational study retrospectively reviewed red cell genotyping data of 150 South African National Blood Service donors whose blood samples were referred to the Immunohaematology Reference Laboratory between January 2015 and August 2016.

The study population of 150 donors comprised 58 conveniently selected serology-determined rare blood type donors and 92 randomly selected Group O, RhD+ donors (Table 1). The selection bias for Group O+ donors was because the South African National Blood Service donor recruitment strategy focuses on sourcing mainly Group O+ blood since it is a common blood type in South Africa and can be transfused to A+, B+, AB+ and O+ patients. The self-proclaimed race groups of the donors as stated on the blood donation donor questionnaire were collated to establish whether there is an association between red cell genotypes, rare blood types and race groups. Donors indicated their self-proclaimed race groups as either Black, mixed race, Indian or White. These racial groups were introduced by apartheid and remain a description of the South African society with Black South Africans being the native Black African population, mixed race South Africans describing a person of mixed European (‘White’) and African (‘Black’) or Asian ancestry, as officially defined by the South African government from 1950 to 1991, Indian South Africans are South Africans who descend from migrants who arrived from British-ruled India during the late 1800s and early 1900s and White South Africans are South Africans of European descent, as well as from certain parts of West Asia. Since the samples of donors were collected nationally within South Africa, all race groups have representation in the study although not of equal distribution.

DNA extraction

DNA was extracted from blood collected in ethylene-diamine-tetraacetic-acid anticoagulated blood tubes using the Maxwell AS2000 (Promega, Madison, Wisconsin, United States) instrument and the Promega Maxwell standard elution volume assay. DNA was quantified using the Nanodrop 2000 (ThermoFisher Scientific, Waltham, Massachusetts, United States) then diluted to obtain a standard DNA concentration of 20ng/µL with a purity falling between 1.7 and 1.9 as required for completion of the ID CORE XT assay (Progenika, Derio, Spain).

ID CORE XT assay

To maximise resources, the Immunohaematology Reference Laboratory utilised the ID CORE XT assay kit (Progenika/Grifols, San Antonio, Texas, United States). The ID CORE XT kit covers red cell antigens or alleles of 10 blood grouping systems: RHCE, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Cartwright and Lutheran, totalling 37 red cell antigens in a single test. The ID CORE XT kit was assayed in a Luminex 200IS analyser (Luminex Corporation, Austin, Texas, United States) to detect beads coated with specific single nucleotide polymorphisms. The BIDSXT assay was used to exclude all invalid red cell genotypes that did not yield a bead count of greater than 30 or a median fluorescent intensity of 1000.

Data analysis

The predicted phenotypes and genotypes were exported from the BIDS XT (Progenika/Grifols, San Antonio, Texas, United States) software to a PowerBI software programme. Simultaneously, demographic details of gender, race, ABO group and RhD types were exported from the organisation’s information system to the business intelligence information technology database to study associations between these characteristics.
| Blood groups† | ID Core XT          | Occurrence (n = 150) | Race         |
|-------------|---------------------|----------------------|--------------|
|             |                     | n   | %    | White (n = 61) | Black (n = 59) | Indian (n = 19) | Mixed race (n = 11) |
| Rh-negative | Ce/ce (r)           | 11  | 7.3  | 10 | 1 | - |
| Rh-negative | Ce/ce (r')          | 8   | 5.4  | 1  | 4 | - |
| Rh-negative | Ce/Ce(r')           | 1   | 0.7  | 1  | - | - |
| Rh-positive | Ce/ce (R'')         | 4   | 2.7  | 1  | - | 3 |
| Rh-positive | Ce/ce (R')          | 1   | 0.7  | 1  | - | - |
| Kell        | k+ Kpb+ Jsb+        | 126 | 84   | 51 | 48 | 17 | 10 |
| Kell        | k+ Kpb+ Jsb-        | 6   | 4.0  | 5  | - | 1 |
| Kell        | k+ Kpb+ Jsb+        | 6   | 4.0  | -  | 5 | - | 1 |
| Kell        | k+ Kpb+ Jsb-        | 6   | 4.0  | -  | 5 | - | 1 |
| Kell        | k+ Kpb+ Jsb+        | 5   | 3.3  | 5  | - | - |
| Kell        | k+ Kpb+ Jsb-        | 1   | 0.7  | 1  | - | - |
| Kidd        | Jka+, Jkb+          | 75  | 50.0 | 18 | 43 | 10 | 4 |
| Kidd        | Jka+, Jkb+          | 48  | 32.0 | 24 | 14 | 7 | 3 |
| Kidd        | Jkb+, Jkb+          | 27  | 18.0 | 19 | 2  | 2 | 4 |
| Duffy       | Fya-, Fyb-          | 47  | 31.3 | 5  | 39 | 1 | 2 |
| Duffy       | Fya+, Fyb+          | 39  | 26.0 | 22 | 2  | 10 | 5 |
| Duffy       | Fyb+                | 27  | 18.0 | 20 | 4  | 2 | 1 |
| Duffy       | Fyb+                | 18  | 12.0 | 5  | 12 | - | 1 |
| Duffy       | Fya+, Fyb+          | 14  | 9.3  | 8  | - | 6 |
| Duffy       | Fya+, Fyb+          | 4   | 2.7  | -  | 2 | - | 2 |
| Duffy       | Fya+ Fyb            | 1   | 0.7  | 1  | - | - |
| MNS – MN    | M+, N+              | 73  | 48.7 | 30 | 28 | 11 | 4 |
| MNS – MN    | GYPAM, GYPAN        | 55  | 36.7 | 22 | 21 | 7 | 5 |
| MNS – MN    | GYPAM, GYPAM        | 22  | 14.7 | 10 | 9 | 1 | 2 |
| S-s-U       | S-s+                | 74  | 49.3 | 30 | 29 | 13 | 2 |
| S-s-U       | GYPB*, GYPB*        | 1   | 0.7  | -  | 1 | - |
| S-s-U       | GYPB*, GYPB*<sub>+</sub> | 1 | 0.7 | - | 1 | - |
| S-s-U       | GYPB*, GYPB*<sub>s</sub> | 36 | 24.0 | 15 | 17 | 2 | 2 |
| S-s-U       | GYPB*, GYPB*<sub>s</sub> | 27 | 18.0 | 6 | 5 | 4 | 12 |
| S-s-U       | GYPB*, GYPB*<sub>s</sub> | 2 | 1.3 | - | - | 2 |
| S-s-U       | GYPB*, GYPB*<sub>s</sub> | 5 | 3.3 | 1 | 3 | - | 1 |
| S-s-U       | GYPB*, GYPB*<sub>s</sub> | 1 | 0.7 | - | 1 | - |
| S-s-U       | GYPB*, GYPB*<sub>deletion</sub> | 3 | 2.0 | 1 | - | 2 |
| Diego       | Dia-, Dib+          | 150 | 100.0 | 61 | 59 | 19 | 11 |
| Dombrock    | Dob+, Dob+          | 67  | 44.7 | 25 | 31 | 8 | 3 |
| Dombrock    | Dob+, Dob+<sub>HY</sub> | 6 | 4.0 | - | 6 | - |
| Dombrock    | Dob+, Dob+<sub>HY</sub> | 1 | 0.7 | 1 | - | - |
| Dombrock    | Dob+, Dob+<sub>JO</sub> | 4 | 2.7 | - | 4 | - |
| Dombrock    | Dob+, Dob+<sub>HY</sub> | 1 | 0.7 | - | 1 | - |
| Dombrock    | Dob+, Dob+<sub>JO</sub> | 23 | 15.3 | 12 | - | 7 | 4 |
| Dombrock    | Dob+, Dob+<sub>JO</sub> | 1 | 0.7 | - | 1 | - |
| Dombrock    | Dob+, Dob+<sub>JO</sub> | 1 | 0.7 | 1 | - | - |
| Colton      | Coa+, Coa+          | 146 | 97.3 | 57 | 59 | 19 | 11 |
| Colton      | Coa+, Coa+<sub>HY</sub> | 4 | 2.7 | 4 | - | - |
| Cartwright  | Yta+, Yta+          | 142 | 94.7 | 58 | 59 | 14 | 11 |
| Cartwright  | Yta+, Yta+<sub>B</sub> | 7 | 4.7 | 3 | 0 | 4 | 0 |

Table 1 continue on next page →
Database collation

The occurrence of the genotypes and predicted phenotypes were analysed from the most to the least occurring among the White, Black, Indian and mixed South African race groups. Rare blood types are either negative for HFA, positive for low-frequency-antigens or unusual, rare Rh subtypes that occur in less than 1% in a population. However, due to the small sample size of the study and the 34 rare blood types that were conveniently added to the study, we could not use the less than 1% guideline. Instead, the rare blood types currently listed on the South African Rare Donor file was used to separate the rare blood types – HrB–, HrS–, k–, Jsb–, U–, Kpb–, Yta–, Lub–, Hy–, Joa–, Uvar+, Cw+, r’r”, r”r, r'’r and RjRj genetically tested in this study.

Results

Most of the study participants were men (63%, n = 95/150) with 80% of the race group distribution comprising 41% (n = 61) White donors and 39% (n = 59) Black South African donors. The 2015–2016 red cell genotyping data was skewed by a selection bias for Group O+ (71%, n = 107) donors which accounted for 33 rare blood types found in 32 donors. In comparison, Group O– donors that made up 13% (n = 20) of the study population showed the presence of 15 rare blood types in 14 donors. The remaining 16% (n = 23) of the Group A+/– and Group B+/– had four rare blood types in four donors, cumulatively resulting in a total of 50 rare donors with 52 rare blood types at a molecular level. Of the 58 serological known rare donors, 44 donors had the serologically defined rare blood types HrB–, HrS–, k–, U–, U-variant+, Jsb, Kpb+, r’r, RzR1, Lub– and Yta– that are covered by the ID CORE XT. However, molecular genotype correlated with serotype in only 34 of the 44 donors (Figure 1). Ten of the 44 serology-defined rare blood types were absent upon molecular testing giving a 23% discrepancy rate between serotyping and genotyping. More so, rare blood types previously not detected by serology were found in two of these 10 donors (Figure 1). Fourteen of the 58 serologically known rare donors had one of the eight rare blood types: Bombay Oh, Vel–, Kna–, In(Lu), LAN–, Dantu–, Milton (Mi II) and Henshaw that were not covered in the ID CORE XT assay. Therefore, these could not be confirmed genotypically (Figure 1).

From among the 92 random donors, genetic and molecular screening identified an additional 14 donors with a total of 16 rare blood types. This brings the total number of rare donors confirmed using genotyping to 50, which comprises 33.3% of the study population (Figure 1).

RhD/RHCE

The most occurring RhD/RHCE phenotype was the Rh-positive Ro (cDe/cDe) phenotype and was found in a majority (72%, n = 42/59) of the South African Black donors. Six Black Ro donors were associated with the rare blood genotype RHCE*ceAR,RHCE*ceARandRHCE*ceAR,RHCE*ce[712G], representing the rare negative HFA, HrS–. In comparison, the White South African donors showed the most genetic variability, having all of the Rh-negative and Rh-positive subtypes. A rare RzRI (CDE/CDE) phenotype occurred in one mixed race South African donor. The four Black and three mixed race South African donors with the r’r (Cde/cde) phenotype were associated with the rare blood genotype RHCE*ce[733G,1006T], RhD*rs-RHCE*ce[733G,1006T] that is serologically referred to as the known negative for a HFA Rh-34 or HrB–. Predominant among the Indian South African donors was the RHCE*Ce, RHCE*Ce, RjRj (CDe/CDe) genotype and predicted phenotype.

Kell

The single nucleotide polymorphisms in ID CORE XT cover the K/k, Kpa/Kpb and Jsa/Jsb antigens from the Kell blood group system (Table 1). The homozygous KEL*KPB_JS, KEL*KPB_JS was the most predominant Kell blood group genotype found across the ethnicities in 84% (n = 126) of the study population. The remaining five Kell genotypes were distributed among 16% (n = 24) of the race groups with the KEL*KPA_JS, KEL*KPA_JS (serologically referred to as the Kpb-) phenotype being the least common Kell genotype in this study.

Kidd

The most occurring Kidd genotype in the study population was the homozygous JK*A, JK*A Kidd blood type. It was observed in 50% (n = 75) of the study population and the majority of the Black and Indian donors. The remaining 50% of the donors had the heterozygous JK*A, JK*B and the homozygous JK*B, JK*B. The three Kidd genotypes...
Study population

N = 150 donors

Serological known rare donors

Not Detected by
ID CORE XT:

Detected by
ID CORE XT:

Random donors

(n = 92)

(n = 44 donors)

(n = 58)

Common genotypes

New rare genotypes

(n = 78 donors)

(n = 14 donors)

(n = 14 donors)

Discrepant§

(n = 10), 2 new rare donors

Correlation

(as detected by red cell genotyping)

Total rare donors – 50

†Forty-four of the 58 serologically determined rare blood donors accounted for 11 rare blood types that are detected by the ID CORE XT assay; †Fourteen of the 58 serologically known rare donors accounted for eight rare blood types (Bombay oh, Ve–, Kn–, In(u), LaN–, Dantu–, Milton (Mi II) and Henshaw) that are not detected by the ID CORE XT assay and therefore could not be confirmed genotypically. †Ten of the 43 serological known rare blood donor types were discrepant upon testing with the ID CORE XT assay; however, two new rare types were identified from two donors.

FIGURE 1: Breakdown of the study population and the resultant total of 50 genetically identified donors based on retrospective red cell genotyping obtained from the South African National Blood Service, Immunohaematology Reference Laboratory over the period January 2015 – August 2016.

were found in almost equal spread among the mixed race donors and the JK*A, JK*B was more common among the White donors.

Duffy

The predominant occurrence of the GATA mutation indicates the predicted Fya–, Fyb– phenotype as present in 31.3% (n = 47) of the study population (Table 1). The FY*B_GATA, FY*B_GATA was predominant among the Black donors while the FY*B, FY*B[265T]_FY*X was observed in one White donor.

MNS

In the ID CORE XT assay, the GYPB and GYPB genes identifying the MN and S-s-U alleles of the MNS system are identified and reported individually. The relationship between the Ss null alleles resulting in U-antigen variants (U-variant) and the GYPB gene deletion resulting in a U-predicted phenotype is evident (Table 1). The rare S-s-U– was found in only the Black donors in this study.

Diego

No DI*A genotype was detected among study participants; however, the homozgyous DI*B, DI*B was detected (Table 1).

Dombrock, Colton, Cartwright, Lutheran

There was a slightly higher occurrence of the homozgyous DO*B, DO*B than the DO*A, DO*B genotype, and there were four Dombrock variants that occurred in less than 1% of the donors. The homozgyous CO*A, CO*A, YT*A, YT*A and LU*B, LU*B genotypes occurred in more than 90% of the study population. A small percentage (2.7%, n = 4) of White donors had the CO*A, CO*B genotype while the YT*B, YT*A, LU*A, LU*A occurred in less than 1% of donors.

The International Society of Blood Transfusion’s categories of rare blood types include: Negative for HFA, positive for low-frequency-antigens and rare unusual Rh subtypes. There were 10 negative for HFAs detected in 38 donors of which the HrB– and HrS– HFA were most common being found in 12 and 6 donors. The two positive for low-frequency-antigensme and four rare Rh subtypes were found among seven donors. Of the 52 rare blood types listed on Table 2, 1% (n = 16) rare blood types were newly identified from 14 donors; two donors had two rare blood types each: HrS– with Jsb– and U– with Dob–. The 1% new rare blood types comprised of 3 HrB–, 3 Jsb–, 2 U-variant (Uvar+), 2 Dob– (DO*A, DO*A_JO), 2 r'r', 1 HrS–, 1 CeCw, 1 r'r, and 1 U–.

Discussion

Studying the red cell genetic variation among the four major South African race groups showed that the Rh subtype R, is found in 42 out of 59 Black donors, R R, in 10 out of 19 Indian donors while six different Rh subtypes are spread among the White donors. Also, rare blood types such as the HrB– and HrS– were found more in Black donors while other rare types such as k–, Kpb– were found among White donors suggesting genetic association between Rh subtype, race group and blood type. This knowledge allows for more effective rare donor screening strategies to be implemented to enhance rare donor-patient blood matching in South Africa. In this study, screening of random Group O+ donors identified 14 new rare donors that would have been missed by routine testing. Hence, identifying markers suggesting a rare blood type in donors such as Rh subtype, race and patterns of genetic variations will assist the development of algorithms for rare blood type testing and identification in donors.

On comparing our results to those from historical serological prevalence studies,11 we observed that White and Indian South Africans share similar alleles for the RHCE*ce/ce, *Ce/cE, KEL*K_KPB_JSB (k–), FY*A, FY*A and YT*A, YT*B genotypes.11 Similarly, common red cell antigens among the Black and mixed race South Africans were the RHCE*cde/Cde, KEL*k_KPB_JSB/JSA and FY*A/B_GATA.11

According to the Department of Statistics South Africa,10 the four major race groups are defined as Black, White, Indian and mixed race people while internationally and outside Africa, the broadly defined ethnic groups are termed Caucasian, African American, Asian, other or mixed race. It has been proposed that global emigration patterns account for the red cell antigens of White South Africans being related to Caucasians, whereas Black and mixed race South Africans are similar to African Americans and Indian South
African similar to Asians, and in some cases, Caucasians. In this study, the presence of the RHCE*Ce/cDe/cDe (r’t’) rare phenotype was not identified in the African donors and Caucasians or Europeans, it is evident that some uniqueness exists between the two geographic regions. The HrB– subtype, the absence of the ‘E’ antigen combined with the HrS– (E-HrB–) indicates the true rare blood type. Besides, the ID CORE XT assay does not differentiate the HrS– (Rh:-31) from hrB– (Rh:-34) samples. The formation of anti-HrB is due to the absence of the high-frequency antigen HrB (HrB–) and anti-HR (Rh:-34) is an ‘anti-e-like’ antibody. The absence of the ‘E’ antigen together with the HrB– (E-HrB–) indicates the true rare blood type. The ID CORE XT assay does not differentiate the HrS– (Rh:-18) from hrB– (Rh:-19) subtype. Similar to the HrB– subtype, the absence of the ‘E’ antigen combined with the HrS– subtype indicates the rare antigen type. This study had revealed a possible differentiation of the two HrB–/hrB– and HrS–/hrS– types due to the presence of specific single nucleotide polymorphisms in the genotype and in comparison to genotype patterns produced when historically known HrB– (Rh:-34) samples are genotyped. This is reflected in Table 2 where the r’s haplotype was used to determine the final phenotype. These subtypes are rare because they are found in less than 1% of the population in a country.

The RHCE*Ce/Ce genotype is a rare Rh subtype (R, R) that was found in one mixed race South African. A study completed by Sharma et al. reported R, R to be found in 6% of Native Americans and 2.2% of Indians in Central India. The low prevalence antigen RHCE*Cw was found in two White South Africans only.

The ID CORE XT assay does not differentiate the HrB– (Rh:-34) from the hrB– (Rh:-31). The formation of anti-HrB is due to the absence of the high-frequency antigen HrB (HrB–) and anti-HrR (Rh:-31) is an ‘anti-e-like’ antibody. The absence of the ‘E’ antigen together with the HrB– (E-HrB)– indicates the true rare blood type. Besides, the ID CORE XT assay does not differentiate the HrS– (Rh:-18) from hrS– (Rh:-31) subtype.

The rare negative high-frequency antigens k–, Kp(b–), Jk(b–), Jo(a–) were found only in White donors and this is consistent with reports in Europeans and Caucasians from America and Europe. The Fy(a-b–) rare phenotype was not identified in the current study and may be attributed to the purposive sampling techniques used in the study. The GATA mutation identified by the ID CORE XT assay predicts Fy(a–b–); however, this is not the true rare phenotype, but rather an assay limitation.

Similar to the European study by Finning et al., three of the negative for HFA Js(b–), Kp(b–) and Jk(b–) were also found in the current study. Although there have been suggested similarities between South African White donors and Caucasians or Europeans, it is evident that some uniqueness exists between the two geographic regions.
The genotype GYPB*S, GYPB*S or s− phenotype is currently not listed as a rare type in South Africa as it is not difficult to locate; however, s− is listed on the rare donor files of Spain and Japan. Although the S-s-U− phenotype predicted by the GYPB*deletion is rare in Caucasians and found mainly in African Americans, it was found in one White and one Black donor in the present study. This suggests the presence of this rare blood type among White South Africans. Interestingly, this study revealed many null alleles among the Ss alleles of the MNS blood group system, which was missed by serology. These are important as the null alleles were mainly associated with the presence of the U-variants. Patients with U-variant phenotypes can only be given blood matched from U-variant donors or risk the formation of anti-U antibodies that will result in transfusion reactions.

Three red cell antigens, the Jk(a−b−), Co(a−) and Ko, were not identified in the present study which could be explained by the small sample size. However, for donors for these three antigens were previously active rare donors on the South African Rare Donor file but became lapsed donors having not donated blood in over 3 years. This highlights the need to increase stores of rare blood units in frozen storage so that patient-donor blood matching is not challenged by the lack of active blood donors. Mass-scale cost-effective red cell genotyping can be used to screen donors routinely for this purpose in line with international practice as in the United States.

The most important finding of this study was that among the mixed race group, 73% (8/11) of the donors showed the presence of rare antigens. Thus, mass-scale rare donor screening among mixed race donors can increase the pool of donors with rare blood types.

Limitations

A limiting factor of the ID CORE XT assay is that several rare red cell antigens in South Africa such as the Rhnull, Kn(a−), Lan−, Bombay Ov, Vel−, Adult I−, Ge−, Inb−, rare ABO subtypes and RhD/RhCE hybrids are not covered by the assay. Due to the small study sample size, genotypic findings must be confirmed in large-scale studies that include all South African ethnic groups that will be representative of the South African donor population.

The study is the first comprehensive red cell genotyping study undertaken at the South African National Blood Service and for South Africa. The extensive gene/antigen coverage of 10 blood groups systems in a single test translates to cost efficiencies, the possibility of high-throughput testing and easier detection of rare blood types present in more than one blood group. This study is also hypothesis-generating, and a few critical areas for future studies have been identified.

Conclusion

This study has highlighted that random screening using molecular red cell genotyping increased the chances of finding rare donors by 15% (n = 14/92 random donors screened). It was further concluded that targeted screening using Rh subtypes associated with race will increase the likelihood of identifying more rare blood donors.

The competition between various commercial companies to provide faster, cost-effective genotyping kits with multiplex ability and high-throughput volumes has made it possible to introduce affordable mass-scale genotyping in South Africa. This will also enable the creation of a substantial local South African red cell genotype database that can be expanded to include the rest of Africa.

Acknowledgements

We acknowledge the staff of the Immunohaematology Reference Laboratory for the completion of red cell genotyping using the ID CORE XT assay. We wish to express our gratitude to the supervisors of L.G.’s master’s thesis for their intellectual assistance.

Competing interests

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Authors’ contributions

L.G. completed the study as part of her dissertation for her Master’s in Medical Laboratory Science completed in 2019 and is the main author of this manuscript. R.D.P., P.P. and U.J. supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.

Sources of support

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Data availability

The authors confirm that the data supporting the findings of this study are available within the article.

Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.

References

1. Daniels G. Human blood groups. John Wiley & Sons, Hoboken, NJ; 2008.
2. Suddock JT, Crookston KP. Transfusion reactions. InStatPearls, Treasure Island, FL; 2019.
3. Daniels G, Hadley A, Soothill P. Blood group antibodies in haemolytic disease of the fetus and newborn. Allimmune Disorders of Pregnancy. 2002;1:21-40. https://doi.org/10.1017/CBO9780511515704.004
4. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14(1):44–61. https://doi.org/10.1054/brle.1999.0123
5. Kutner J, Mota M, Conti F, et al. Blood genotyping for improved outcomes in chronic transfusion patients: Current and future perspectives. Int J Clin Transfus Med. 2014;2014(2):65–72. https://doi.org/10.2147/IJCTM.S48394

6. Wilkinson DS. Clinical utility of genotyping human erythrocyte antigens. Lab Med. 2016;47(3):e28–e31. https://doi.org/10.1093/labmed/lmw014

7. Nance ST. Global definitions of rare donors. ISBT Sci Ser. 2013;8(1):23–27. https://doi.org/10.1111/voxs.12006

8. Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood. 2009;114(2):248–256. https://doi.org/10.1182/blood-2008-11-146860

9. Giraner T, Belay S, Chiaroni J, et al. A comprehensive survey of both RHD and RHCE allele frequencies in sub-Saharan Africa. Transfusion. 2013;53(11pt2): 3009–3017. https://doi.org/10.1111/trf.12409

10. Department of Statistics South Africa. Community survey 2016, Statistical Release P0301, East London, Eastern Cape. [statssa.gov.za] [homepage on the Internet]. Statistical release report 2016. 2016 [cited 2020 Feb 21]. Available from: http://cs2016.statssa.gov.za/wp-content/uploads/2016/07/NT-30-06-2016-RELEASE-for-CS-2016-_Statistical-releas_1-July-2016.pdf

11. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. Academic Press, Cambridge, MA; 2012.

12. Patin E, Lopez M, Grollemund R, et al. Dispersals and genetic adaptation of Bantu-speaking populations in Africa and North America. Science. 2017;356(6337): 543–546. https://doi.org/10.1126/science.aai1988

13. Ramerini M. Dutch-Portuguese colonial history. Marco Ramerini, Cape Town; 1998.

14. Zheng Y, Du X, Cui Y, et al. The genetic structure and history of Africans and African Americans. Science [serial online]. 2009 [cited 2018 Jul 19];324(5930):1035–1044. Available from: http://science.sciencemag.org/

15. Poole J. The international rare donor panel. ISBT Sci Ser. 2006;1(1):209. https://doi.org/10.1111/j.1751-2824.2006.00031.x

16. Flickinger C. The American rare donor program. Immunohematology. 2016;32(2):71–73. https://doi.org/10.21307/immunohematology-2019-049

18. Muñiz-Díaz E, Castro A, Flores E, et al. The Spanish program for rare blood donors. Immunohematology. 2016;32(2):59–61. https://doi.org/10.21307/immunohematology-2019-046

19. Huxtrin H, Lejon Crottet S, Scharberg EA. Rare donor programs in Switzerland, Germany, and Austria. Immunohematology. 2016;32(2):63–66. https://doi.org/10.21307/immunohematology-2019-047

20. Moores P. Rh18 and hr5 blood groups and antibodies. Vox Sanguinis. 1994;66(3):225–230. https://doi.org/10.1159/000462513

21. Moores P, Smart E. Serology and genetics of the red blood cell factor Rh34. Vox Sanguinis. 1991;61(2):122–129. https://doi.org/10.1159/000463136

22. Poole J. The international rare donor panel. ISBT Sci Ser. 2006;1(1):209. https://doi.org/10.1111/j.1751-2824.2006.00031.x

23. Tani Y. Rare donor program in Japan. Immunohematology. 2016;32(2):49–50. https://doi.org/10.21307/immunohematology-2019-041

24. Karah MA, Patel RD. Phenotype frequencies of blood group systems (Rh, Kidd, Duffy, MNS, P, Lewis, and Lutheran) in blood donors of south Gujarat, India. Asian J Transfus Sci. 2014;8(1):51. https://doi.org/10.4103/0973-6247.126693

25. Goldman M, St Croix L. Rare donor program: Canadian blood services. Immunohematology. 2016;32(1):15–16. https://doi.org/10.21307/immunohematology-2019-033

26. Finning K, Bhandari R, Sellers F, et al. Evaluation of red blood cell and platelet antigen genotyping platforms (ID CORE XT/ID HPA XT) in routine clinical practice. Blood Transfus. 2016;14(2):160.

27. Sharma DC, Singhal S, Rai S, et al. Incidence of Rh antigens, phenotype & probable genotype in the population of Gwalior and Chambal region, Central India. Int Blood Res Rev. 2013;11(1):29–43. https://doi.org/10.9734/IBRR/2013/4616

28. Avent ND, Martínez A, Flegel WA, et al. The bloodgen project of the European Union, 2003–2009. Transfus Med Hemother. 2009;36(3):162–167. https://doi.org/10.1159/000218192

29. Smart E. South African rare donor panel. ISBT Sci Ser. 2006;1(1):210–212. https://doi.org/10.1111/j.1751-2824.2006.00032.x

30. Noumsi GT, Billingley KL, McCaskill D, et al. Effectiveness of high-throughput blood group genotyping on building a rare donor database. Transfusion. 2014;54:57A–57A.